Nuveen AMT-Free Municipal Value Fund NUW 深 滬
已收盤 10-17 16:00:00 美东时间
14.17
-0.040
-0.28%
華盛通- 最 高14.22
- 今 開14.18
- 成交量 3.32万股
- 最 低 14.14
- 昨 收 14.21
- 總市值 2.54亿
- 52周最高 14.4715
- 市盈率 靜 9.38
- 換手率 0.18%
- 52周最低 12.7005
- 委 比 86.67%
- 總股本 1795.13万
- 歷史最高 15.5276
- 量 比 1.59
- 振 幅 0.56%
- 歷史最低 9.1406
- 每 手 1
- 風險率 0.29%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Nuwellis Announces 92% Survival in Children with Acute Kidney Injury (AKI), Fluid Overload or Congenital Kidney Failure Following Treatment with Aquadex®
The ULTRA-Peds registry, a multi-center observational study, shows Aquadex therapy is well-tolerated and effective in critically ill children with acute kidney injury, fluid overload, or congenital kidney failure. Findings include 92% patient survival, 66% survival to discharge, and 86% completion of intended treatment course. Results highlight the need for pediatric-specific devices like Vivian, Nuwellis’ CRRT system under development for neonat...
09-30 12:45
Nuwellis Receives New US Patent Reinforcing Vivian™ Pediatric Device Focused on Safer, More Precise Ultrafiltration
Nuwellis, Inc. has been granted U.S. Patent No. 12,415,021 for hemolysis sensing technology in extracorporeal blood filtration systems, aiding in detecting and localizing red blood cell destruction. This innovation supports their pediatric device, Vivian, and enhances safety in ultrafiltration therapy. Hemolysis, the breakdown of red blood cells, can pose serious risks, and existing detectors often fail to detect hemolyzed blood. The patent enabl...
09-18 13:00
Serco awarded $97 Million U.S. Navy Submarine Communication Contract
Serco (OTCPK:SECCF) on Wednesday said, it has been awarded a $97 million contract by the U.S. Navy to continue supporting the Submarine High Data Rate (SubHDR) antenna systems. The contract, an indefi...
09-10 20:56
Nuwellis’ Vivian Receives $3 Million NIH Grant to Accelerate Pediatric Platform and Strengthen Fluid-Management Portfolio
Nuwellis Inc. announced it received a $3 million NIH grant to support the development of Vivian™, a pediatric CRRT device designed for patients weighing 2.5–20 kg. Currently, limited options exist for infants and small children with kidney failure, often requiring adult technologies adapted for their use. Vivian aims to address this gap with a pediatric-specific system featuring precise fluid management, integrated sensors for real-time monitorin...
09-09 13:00
Nuwellis Introduces New 24-Hour Aquadex™ Circuit to Support Hospital-Based Outpatient and Short-Term Fluid Management
Nuwellis, Inc. announced plans to launch a new 24-hour Aquadex therapy circuit in the U.S. this fall to support single-day outpatient sessions, complementing its existing 72-hour option for multi-day or inpatient care. This addition aims to help hospitals align Aquadex therapy with outpatient workflows, improve efficiency, and expand access for patients needing fluid removal without hospitalization. The 24-hour circuit supports predictable care s...
09-04 12:15
【上证机器人】看好富士康机器人产业链-人形机器人行业观点报告
（来源：上海证券研究） 1.富士康在机器人领域的相关布局 1)2006年，公司自主研发生产的“富士康深圳一号”机器人亮相深圳第八届高交会；根据《一步步新技...
08-27 17:14
Nuwellis to Exit International Operations to Accelerate U.S. Revenue Growth and Strategic Focus
Nuwellis, Inc. announced its decision to exit international operations and focus exclusively on the U.S. market due to stronger growth and clinical demand there. The company aims to prioritize investment in high-impact areas like U.S. cardiac surgery, pediatrics, and outpatient care. This strategic move aligns operations with market demand and aims to deliver better patient outcomes and shareholder value. Nuwellis will continue supporting interna...
08-07 12:15
Nuveen AMT-Free Municipal Value Fund declares $0.0485 dividend
Nuveen AMT-Free Municipal Value Fund (NYSE:NUW) declares $0.0485/share monthly dividend. Forward yield 4.26% Payable Sept. 2; for shareholders of record Aug. 15; ex-div Aug. 15. See NUW Dividend Score...
08-05 20:50
Nuwellis Announces the First Successful Outpatient Application of the Aquadex Smartflow® System Under New CMS Code
Nuwellis, Inc. announced successful treatment of first patients with Aquadex ultrafiltration therapy in a hospital-based outpatient setting, supported by increased reimbursement rates. This milestone improves access to fluid management and offers potential economic and clinical advantages for hospitals and patients.
08-05 12:15
Nuwellis Stockholders Approve All Proposals at Special Meeting
Nuwellis, Inc. announced that its Special Meeting of Stockholders approved all proposals aimed at enhancing financial flexibility and supporting strategic growth. These include the issuance of shares under warrants, increasing authorized common stock from 100 million to 200 million, and authorizing a reverse stock split ratio between 1-for-5 and 1-for-70. CEO John Erb thanked stockholders, noting these approvals strengthen Nuwellis's capital posi...
08-04 21:24
